{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:58:11Z","timestamp":1790629091559,"version":"4.1.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"DOI":"10.1186\/s40164-026-00833-w","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T07:23:41Z","timestamp":1790580221000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Daraxonrasib and the era of pan-RAS inhibition: mechanisms, clinical advances, and resistance landscapes"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3109-7266","authenticated-orcid":false,"given":"Jiacheng","family":"Lou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danlu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"833_CR1","doi-asserted-by":"crossref","unstructured":"Holderfield M, Lee BJ, Jiang J, Tomlinson A, Seamon KJ, Mira A et al. Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy. Nature. 2024:919\u201326.","DOI":"10.1038\/s41586-024-07205-6"},{"issue":"12","key":"833_CR2","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.3390\/ph18121788","volume":"18","author":"FE Alanazi","year":"2025","unstructured":"Alanazi FE, Alatawi Y, Alattar A, Alshaman R, Kotb AA, Hetta HF. Broad-Spectrum RAS Inhibition in Pancreatic Ductal Adenocarcinoma: Mechanistic Advances and Therapeutic Promise. Pharmaceuticals (Basel). 2025;18(12):1788.","journal-title":"Pharmaceuticals (Basel)"},{"key":"833_CR3","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41586-023-06123-3","volume":"619","author":"D Kim","year":"2023","unstructured":"Kim D, Herdeis L, Rudolph D, Zhao Y, B\u00f6ttcher J, Vides A, et al. Pan-KRAS inhibitor disables oncogenic signalling and tumour growth. Nature. 2023;619:160\u20136. https:\/\/doi.org\/10.1038\/s41586-023-06123-3.","journal-title":"Nature"},{"key":"833_CR4","doi-asserted-by":"crossref","unstructured":"Fivaz M, Bornand A, Corro C, Koessler T, Genoud V. Actionable mutations in pancreatic cancer: where targeted therapies are making a difference. BMJ Open Gastroenterol. 2025;12(1):e001925.","DOI":"10.1136\/bmjgast-2025-001925"},{"key":"833_CR5","doi-asserted-by":"crossref","unstructured":"Canaslan K, Basbinar Y, Oztop I. From G12C To pan-RAS: the expanding therapeutic landscape of KRAS-mutant NSCLC. Crit Rev Oncol Hematol. 2026:105344.","DOI":"10.1016\/j.critrevonc.2026.105344"},{"key":"833_CR6","doi-asserted-by":"crossref","unstructured":"Chatziioannou E, Lallas K, Sinnberg T, Niessner H, Stratigos AJ, Flatz L et al. Insights into RAS-driven melanoma and its therapeutic implications. Cancer Treat Rev. 2026:103090.","DOI":"10.1016\/j.ctrv.2026.103090"},{"issue":"6","key":"833_CR7","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/j.ccell.2026.03.020","volume":"44","author":"R Entrialgo-Cadierno","year":"2026","unstructured":"Entrialgo-Cadierno R, Morali K, Feliu I, Wang Y, Evans JW, Yanez-Bartolome M, et al. Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma. Cancer Cell. 2026;44(6):1218\u201334.","journal-title":"Cancer Cell"},{"issue":"6","key":"833_CR8","doi-asserted-by":"publisher","first-page":"6064","DOI":"10.1021\/acs.jmedchem.4c02314","volume":"68","author":"J Cregg","year":"2025","unstructured":"Cregg J, Edwards AV, Chang S, Lee BJ, Knox JE, Tomlinson ACA, et al. Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers. J Med Chem. 2025;68(6):6064\u201383.","journal-title":"J Med Chem"},{"key":"833_CR9","doi-asserted-by":"publisher","first-page":"100047","DOI":"10.1016\/j.pscia.2024.100047","volume":"2","author":"W Su","year":"2024","unstructured":"Su W, Hou X. Targeting active RAS with molecular glue. Pharm Sci Adv. 2024;2:100047.","journal-title":"Pharm Sci Adv"},{"key":"833_CR10","doi-asserted-by":"crossref","unstructured":"Wei X, Blaj C, Ali A-RM, Lai LP, Maldonato BJ, Yang YC et al. Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory KRAS G12C-Mutant NSCLC for Immune Checkpoint Blockade. Cancer Discov. 2026:1152\u201375.","DOI":"10.1158\/2159-8290.CD-25-1616"},{"key":"833_CR11","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41586-021-04065-2","volume":"599","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Murciano-Goroff YR, Xue JY, Hoff A, Taylor AM, Chang JC, et al. Diverse alterations associated with resistance to KRAS(G12C) inhibition. Nature. 2021;599:679\u201383.","journal-title":"Nature"},{"key":"833_CR12","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.cell.2020.09.044","volume":"183","author":"D Kim","year":"2020","unstructured":"Kim D, Xue JY, Lito P, Targeting. KRAS(G12C): from inhibitory mechanism to modulation of antitumor effects in patients. Cell. 2020;183:850\u20139.","journal-title":"Cell"},{"key":"833_CR13","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41586-019-1884-x","volume":"577","author":"JY Xue","year":"2020","unstructured":"Xue JY, Zhao Y, Aronowitz J, Mai TT, Vides A, Qeriqi B, et al. Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition. Nature. 2020;577:421\u20135.","journal-title":"Nature"},{"key":"833_CR14","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1158\/2159-8290.CD-24-0027","volume":"14","author":"J Jiang","year":"2024","unstructured":"Jiang J, Jiang L, Maldonato BJ, Wang Y, Holderfield M, Aronchik I, et al. Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers. Cancer Discov. 2024;14:994\u20131017.","journal-title":"Cancer Discov"},{"key":"833_CR15","doi-asserted-by":"publisher","first-page":"104250","DOI":"10.1016\/j.drudis.2024.104250","volume":"30","author":"P Filis","year":"2025","unstructured":"Filis P, Salgkamis D, Matikas A, Zerdes I. Breakthrough in RAS targeting with pan-RAS(ON) inhibitors RMC-7977 and RMC-6236. Drug Discov Today. 2025;30:104250.","journal-title":"Drug Discov Today"},{"key":"833_CR16","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1515\/hsz-2025-0249","volume":"407","author":"P Pfaff","year":"2026","unstructured":"Pfaff P, Shokat KM. GAP mimetic activity of pan-Ras TCI daraxonrasib synergizes with K-Ras Switch-II pocket inhibition. Biol Chem. 2026;407:91\u2013103.","journal-title":"Biol Chem"},{"key":"833_CR17","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1056\/NEJMoa2505783","volume":"394","author":"BM Wolpin","year":"2026","unstructured":"Wolpin BM, Park W, Garrido-Laguna I, Spira A, Starodub A, Sommerhalder D, et al. Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer. N Engl J Med. 2026;394:1790\u2013802.","journal-title":"N Engl J Med"},{"key":"833_CR18","doi-asserted-by":"publisher","unstructured":"Daraxonrasib Doubles. OS for PDAC in Phase III Trial. Cancer Discov. 2026;16(7):OF1. https:\/\/doi.org\/10.1158\/2159-8290.CD-NW2026-0062","DOI":"10.1158\/2159-8290.CD-NW2026-0062"},{"key":"833_CR19","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1016\/j.cell.2026.03.031","volume":"189","author":"B Sang","year":"2026","unstructured":"Sang B, Ye LF, Fu Z, Pourfarjam Y, Cuevas-Navarro A, Fan S, et al. Disrupted molecular glue complex drives RAS inhibitor resistance. Cell. 2026;189:2918\u2013e293317.","journal-title":"Cell"},{"key":"833_CR20","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13045-024-01631-9","volume":"17","author":"X Yang","year":"2024","unstructured":"Yang X, Wu H. RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms. J Hematol Oncol. 2024;17:108.","journal-title":"J Hematol Oncol"},{"key":"833_CR21","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1158\/0008-5472.CAN-25-2764","volume":"86","author":"HV Patel","year":"2026","unstructured":"Patel HV, Smith AE, Chan S, Gasendo JG, Jombik A, Greer JE, et al. The Farnesyl Transferase Inhibitor Darlifarnib (KO-2806) Resensitizes Relapsing. Cancer Res. 2026;86:2273\u201385.","journal-title":"Cancer Res"},{"key":"833_CR22","doi-asserted-by":"crossref","unstructured":"Kumarasamy V, Wang J, Yau E, Abel EV, Witkiewicz AK, Knudsen ES. Targeting Distinct Cell Cycle Nodes Overcomes KRAS\/RAS Inhibitor Resistance. bioRxiv. 2026. https:\/\/pubmed.ncbi.nlm.nih.gov\/41959066","DOI":"10.64898\/2026.03.10.710937"},{"key":"833_CR23","doi-asserted-by":"publisher","first-page":"e2610708123","DOI":"10.1073\/pnas.2610708123","volume":"123","author":"V Liaki","year":"2026","unstructured":"Liaki V, Barrambana S, Kostopoulou M, Lechuga CG, Zamorano-Dominguez E, Acosta-Gallego D, et al. A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance. Proc Natl Acad Sci USA. 2026;123:e2610708123.","journal-title":"Proc Natl Acad Sci USA"},{"key":"833_CR24","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1158\/2159-8290.CD-24-1475","volume":"15","author":"M Orlen","year":"2025","unstructured":"Orlen M, Vostrejs WP, Sor R, McDevitt JC, Kemp SB, Kim IK, et al. T-cell Dependency of Tumor Regressions and Complete Responses with RAS(ON) Multi-selective Inhibition in Preclinical Models of Pancreatic Ductal Adenocarcinoma. Cancer Discov. 2025;15:1697\u2013716.","journal-title":"Cancer Discov"},{"key":"833_CR25","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1158\/2326-6066.CIR-25-0744","volume":"14","author":"DCCL Anastacio","year":"2026","unstructured":"Anastacio DCCL, Tovbis SN, Phadke MS, Emmons MF, Pechuan-Jorge X, Mbuga F, et al. RAS(ON) Multiselective Inhibition Drives Antitumor Immunity in Preclinical Models of NRAS-Mutant Melanoma. Cancer Immunol Res. 2026;14:90\u2013106.","journal-title":"Cancer Immunol Res"},{"key":"833_CR26","unstructured":"Hill RD, Dalton KM, Kurupi R, Slaughter JM, Roberts J, Xing Y et al. Daraxonrasib (RMC-6236) is an effective targeted therapy for RAS-mutant neuroblastoma. bioRxiv. 2026. https:\/\/pubmed.ncbi.nlm.nih.gov\/41756844"},{"key":"833_CR27","doi-asserted-by":"crossref","unstructured":"Jung O, Soto A, Wolfe AL, Mahajan SS. Daraxonrasib, a pan-RAS inhibitor, selectively inhibits osteosarcomas with activated KRAS by halting AKT signaling and matrix metalloprotease activity. PLoS ONE. 2025;20:e0329946.","DOI":"10.1371\/journal.pone.0329946"},{"key":"833_CR28","doi-asserted-by":"crossref","unstructured":"Chowdhury S, Ito I, Pattalachinti VK, Yousef AM, Yousef MM, Khoury SE et al. KRAS inhibition is an effective therapy for appendiceal adenocarcinoma. J Hematol Oncol. 2026. https:\/\/read.qxmd.com\/read\/42393724","DOI":"10.64898\/2026.04.07.717107"},{"key":"833_CR29","doi-asserted-by":"crossref","unstructured":"Bannoura SF, Khan HY, Aboukameel A, Wan Y, Bao B, Uddin MH et al. PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic Cancer. bioRxiv. 2025. https:\/\/pubmed.ncbi.nlm.nih.gov\/41427373","DOI":"10.64898\/2025.12.06.692635"},{"key":"833_CR30","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1038\/s41467-026-68319-1","volume":"17","author":"DA Bonsor","year":"2026","unstructured":"Bonsor DA, Finci LI, Potter JR, Young LC, Wall VE, Goldstein de SR, et al. Structure of SHOC2-KRAS-PP1C complex reveals RAS isoform-specific determinants and insights into targeting complex assembly by RAS inhibitors. Nat Commun. 2026;17:1614.","journal-title":"Nat Commun"},{"key":"833_CR31","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/s41586-024-07379-z","volume":"629","author":"UN Wasko","year":"2024","unstructured":"Wasko UN, Jiang J, Dalton TC, Curiel-Garcia A, Edwards AC, Wang Y, et al. Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Nature. 2024;629:927\u201336. https:\/\/doi.org\/10.1038\/s41586-024-07379-z.","journal-title":"Nature"},{"key":"833_CR32","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1158\/2159-8290.CD-24-0614","volume":"15","author":"M Marasco","year":"2025","unstructured":"Marasco M, Kumar D, Garcia Borrego S, Seale T, Maddalena G, Mezzadra R, et al. Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations. Cancer Discov. 2025;15:1392\u2013409. https:\/\/doi.org\/10.1158\/2159-8290.CD-24-0614.","journal-title":"Cancer Discov"},{"key":"833_CR33","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41586-024-08283-2","volume":"637","author":"A Cuevas-Navarro","year":"2025","unstructured":"Cuevas-Navarro A, Pourfarjam Y, Hu F, Rodriguez DJ, Vides A, Sang B, et al. Pharmacological restoration of GTP hydrolysis by mutant RAS. Nature. 2025;637:224\u20139. https:\/\/doi.org\/10.1038\/s41586-024-08283-2.","journal-title":"Nature"},{"issue":"15","key":"833_CR34","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.3390\/cancers17152453","volume":"17","author":"K Krupa","year":"2025","unstructured":"Krupa K, Fudalej M, Wloszek E, Miski H, Badowska-Kozakiewicz AM, Mekal D, et al. Treatment of KRAS-Mutated Pancreatic Cancer: New Hope for the Patients? Cancers (Basel). 2025;17(15):2453.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"833_CR35","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1158\/1078-0432.CCR-25-2734","volume":"32","author":"AJ Pfeil","year":"2026","unstructured":"Pfeil AJ, Zhang T, Cheng R, Mattar MS, Gomez MJ, Gili L, et al. RRAS and RRAS2 Mutations Are Recurrent Oncogenic Drivers in Lung Cancer and Are Sensitive to the Pan-RAS Inhibitor RMC-6236. Clin Cancer Res. 2026;32(7):1362\u201375.","journal-title":"Clin Cancer Res"},{"key":"833_CR36","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1158\/1535-7163.MCT-24-0386","volume":"24","author":"A Tedeschi","year":"2025","unstructured":"Tedeschi A, Schischlik F, Rocchetti F, et al. Pan-KRAS inhibitors BI-2493 and BI-2865 display potent antitumor activity in tumors with KRAS wild-type allele amplification. Mol Cancer Ther. 2025;24:550\u201362.","journal-title":"Mol Cancer Ther"},{"key":"833_CR37","unstructured":"Foth M, Kim W, O\u2019Toole K, Murphy B, Justo-Garrido M, Boggaram S et al. Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multiselective Inhibitors in NRAS-Mutated Melanoma. Cancer Res. 2026. https:\/\/pubmed.ncbi.nlm.nih.gov\/42171647"},{"key":"833_CR38","doi-asserted-by":"crossref","unstructured":"Arguedas D, Bui V, Law T, Rijmers J, Tissier R, Beijnen JH et al. Daraxonrasib (RMC-6236) pharmacokinetics: impact of transporters and drug-metabolizing enzymes on a first-in-class pan-RAS molecular glue. Pharmacol Res. 2026:108226.","DOI":"10.1016\/j.phrs.2026.108226"},{"key":"833_CR39","doi-asserted-by":"crossref","unstructured":"Mahadevan KK, Maldonado AS, Li B, Bickert AA, Kapercyzk-Perdyan A, Kumbhar SV et al. Distinct small molecule inhibitors of Kras specifically prime CTLA4 blockade therapy to transcriptionally reprogram Tregs and overcome resistance to suppress pancreas cancer. bioRxiv. 2025. https:\/\/pubmed.ncbi.nlm.nih.gov\/40093186","DOI":"10.1101\/2025.02.28.640711"},{"key":"833_CR40","doi-asserted-by":"publisher","first-page":"eadx0632","DOI":"10.1126\/sciadv.adx0632","volume":"14","author":"D Gong","year":"2025","unstructured":"Gong D, Liu R, Cui Y, Rhodes M, Bae JW, Beechem JM, et al. Integrated spatial morpho-transcriptomics predicts functional traits in pancreatic cancer. Sci Adv. 2025;14:eadx0632.","journal-title":"Sci Adv"},{"key":"833_CR41","doi-asserted-by":"crossref","unstructured":"Aston BS, Badmos HA, Cagan R, Macrophage-Derived PDGF-BB. and GDF-15 Promote Drug Resistance in KRAS-Mutant Colorectal Cancer. bioRxiv. 2026. https:\/\/pubmed.ncbi.nlm.nih.gov\/42094384","DOI":"10.64898\/2026.04.27.721111"},{"key":"833_CR42","doi-asserted-by":"crossref","unstructured":"Drugging RAS. Moving Beyond KRAS G12C. Cancer Discov. 2023:OF7.","DOI":"10.1158\/2159-8290.CD-ND2023-0010"},{"issue":"7","key":"833_CR43","doi-asserted-by":"publisher","first-page":"oyag194","DOI":"10.1093\/oncolo\/oyag194","volume":"31","author":"A Kaminsky","year":"2026","unstructured":"Kaminsky A, Suhl S, Sacknovitz Y, Schwartz GK, Deverapalli S, Geskin LJ. Skin Health in Oncology: Evidence-Based Skin Care for Cancer Patients. Oncologist. 2026;31(7):oyag194.","journal-title":"Oncologist"},{"key":"833_CR44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2605555","author":"EM O\u2019Reilly","year":"2026","unstructured":"O\u2019Reilly EM, Wainberg ZA, Hendifar AE, Borad MJ, Pietrantonio F, Pant S, et al. Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer. N Engl J Med. 2026. https:\/\/doi.org\/10.1056\/NEJMoa2605555.","journal-title":"N Engl J Med"},{"key":"833_CR45","first-page":"7529882","volume":"2026","author":"E Huynh","year":"2026","unstructured":"Huynh E, Gregory A, Chang PY. Acral Lentiginous Melanoma with NRAS Mutation and Ocular Surface Toxicity Following Immunotherapy and Investigational KRAS G12C Inhibitor: Case Report. Case Rep Oncol Med. 2026;2026:7529882.","journal-title":"Case Rep Oncol Med"},{"key":"833_CR46","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41417-026-01003-0","volume":"33","author":"D Bhattacharya","year":"2026","unstructured":"Bhattacharya D, Roman B, Reddy S. Therapeutic advances with KRAS(G12C) inhibitors and combination strategies in non-small cell lung cancer brain metastases. Cancer Gene Ther. 2026;33:323\u201337.","journal-title":"Cancer Gene Ther"},{"key":"833_CR47","doi-asserted-by":"publisher","first-page":"1685433","DOI":"10.3389\/fphar.2026.1685433","volume":"17","author":"E Wen","year":"2026","unstructured":"Wen E, Vera C, Kesavan S, Kouassi F, LaComb JF, Zand N, et al. AUM-302, a novel triple PIM\/PI3K\/mTOR inhibitor, synergizes with RAS inhibition and impedes the growth of pancreatic ductal adenocarcinoma spheroids and organoids. Front Pharmacol. 2026;17:1685433.","journal-title":"Front Pharmacol"},{"key":"833_CR48","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1002\/ueg2.70086","volume":"13","author":"J Buchloh","year":"2025","unstructured":"Buchloh J, Spitzner M, Zimmermann H, Fang X, Tapia CC, Schneider C, et al. Pan-ERBB Inhibitors Synergize With KRAS Inhibitors in Rectal Cancer. United Eur Gastroenterol J. 2025;13:1690\u2013702.","journal-title":"United Eur Gastroenterol J"},{"key":"833_CR49","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ygyno.2025.06.022","volume":"200","author":"EH Stover","year":"2025","unstructured":"Stover EH, Lee EK, Shapiro GI, Brugge JS, Matulonis UA, Liu JF. The RAS-MEK-ERK pathway in low-grade serous ovarian cancer. Gynecol Oncol. 2025;200:22\u201332.","journal-title":"Gynecol Oncol"},{"key":"833_CR50","doi-asserted-by":"publisher","first-page":"e2407745121","DOI":"10.1073\/pnas.2407745121","volume":"122","author":"SF Sait","year":"2025","unstructured":"Sait SF, Tang KH, Angus SP, Brown R, Sun D, Xie X, et al. Hydroxychloroquine prevents resistance and potentiates the antitumor effect of SHP2 inhibition in NF1-associated malignant peripheral nerve sheath tumors. Proc Natl Acad Sci USA. 2025;122:e2407745121.","journal-title":"Proc Natl Acad Sci USA"},{"key":"833_CR51","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1038\/s41591-026-04537-w","volume":"32","author":"I Aronchik","year":"2026","unstructured":"Aronchik I, Kar S, Zhuang Y, et al. Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer. Nat Med. 2026;32:2865\u201377.","journal-title":"Nat Med"},{"key":"833_CR52","doi-asserted-by":"publisher","first-page":"101","DOI":"10.21037\/jgo-2025-aw-818","volume":"17","author":"FM Kouassi","year":"2026","unstructured":"Kouassi FM, Patel H, Karnoub ER, Tsang CF, Hohenleitner J, Basturk O, et al. Brain metastasis from KRAS wild-type pancreatic cancer and organoid correlates: a case report. J Gastrointest Oncol. 2026;17:101.","journal-title":"J Gastrointest Oncol"},{"key":"833_CR53","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/CCO.0000000000001042","volume":"36","author":"P Vanclooster","year":"2024","unstructured":"Vanclooster P, Seghers S, Prenen H. State-of-the-art and upcoming trends in RAS-directed therapies in gastrointestinal malignancies. Curr Opin Oncol. 2024;36:313\u20139.","journal-title":"Curr Opin Oncol"}],"container-title":["Experimental Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-026-00833-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-026-00833-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-026-00833-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:03:41Z","timestamp":1790625821000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40164-026-00833-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["833"],"URL":"https:\/\/doi.org\/10.1186\/s40164-026-00833-w","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"21 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this work, the authors used large language model assistants in order to assist with drafting and language editing of the manuscript text, and a Gemini image-generation tool in order to create the illustrations in Figures 1 and 2. After using these tools, the authors reviewed, corrected, and edited all generated content as needed, and take full responsibility for the content of the published article.","order":3,"name":"Ethics","label":"Declaration of generative AI and AI-assisted technologies in the writing process","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"100"}}